Maxygen Holdings Ltd.

Bayer Healthcare LLC

Novozymes A/s

Maxygen Aps

Other

Maxygen, Inc.

Symphogen A/s

Arts Biologics A/s

Torben Lauesgaard Nissen

Kim Vilbour Andersen

Hans Thalsgard Schambye

Jan Moller Mikkelsen

Christian Karsten Hansen

Claus Bornaes

Anders Pedersen

Christian Hansen

Peter Kamp Hansen

Peter Bauditz

Frank Mikkelsen

Anne Dam Jensen

Hans Thalsgaard Schambye

Jesper Haaning

Poul Baad Rasmussen

Claus Von Der Osten

Bart Van Den Hazel

Carsten Schau Andersen

Martin Schulein

Grethe Norskov Rasmussen

Mikkel Wandahl Pedersen

Klaus Koefoed

Michael Kragh

Mads Norregaard-Madsen

Peter Sejer Andersen

Johan Lantto

Helle Jane Jacobsen

Magnus Strandh

Torben Henriksen, Legal Representative

Thomas Tuxen Poulsen

Bo Damgaard

Allan Svendsen

Jesper Vind

Shamkant Anant Patkar

Arne Agerlin Olsen

Kirsten Bojsen

Steffen Ernst

Mads Nørregaard-Madsen

Per Ola Freskgaard

Lars Søgaard Nielsen

Frank Bech Nygaard

Erwin Ludo Roggen

Lars Hylling Christensen

Svend Lindenberg

Peter Nordkild

Dorte Aaby Halkier

Lars Christiansen

Jesper Mortensen Haaning

Paul Baad Rasmussen

Frank Bechnygaard

Ida Kjær

Claes Bornaes

Steven Glazer

Mads Röpke

Lars Sogaard Nielsen

Claus Yding Andersen

Ida Kjaer

Dorte A Halkier

Hans Thalsgärd Schambye

Jan Möller Mikkelsen

Frank F Mikkelsen

Halkier Dorte A A

Anders Hjelholt Pedersen

The invention relates to humanized recombinant antibodies targeting the EGFR family receptors EGFR, HER2 and HER3, compositions comprising at least one humanized anti-EGFR antibody, at least one humanized anti-HER2 antibody and at least one humanized anti-HER3 antibody, and use of the antibody compositions for treatment of cancer. The invention also relates to the use of antibodies targeting multiple EGFR-family receptors to treat cancer (e.g., pancreatic cancer) and cancer that has acquired resistance to previous therapies.

Methods for treating cancer by administering humanized pan-HER antibody compositions

Humanized pan-HER antibody compositions

The present invention relates to novel polypeptide variants of factor VII (FVII) or factor VIIa (FVIIa) polypeptides, where said variants comprise an amino acid substitution in position 10 and 32 and where said variants further comprise a sugar moiety covalently attached to an introduced in vivo N-glycosylation site located outside of the Gla domain. Such polypeptide variants are useful in therapy, in particular for the treatment of a variety of coagulation-related disorders, such as trauma.

Factor VII or VIIa polypeptide variants

The present invention relates to a long acting biologically active luteinizing hormone (LH) compound comprising an LH agonist linked to a pharmaceutically acceptable molecule providing an in vivo plasma half-life of the LH agonist or LH compound which is increased substantially compared to the in vivo plasma half-life of an LH agonist administered in the same manner as the LH compound. The present invention relates to methods for controlled ovarian stimulation which can be used in conjunction with assisted reproduction technologies such as in vitro fertilization, intra cytoplasmatic sperm injection, intra uterine insemination and in vitro maturation. In other aspects the invention relates to methods for inducing folliculogenesis and methods for providing luteal support for the corpora lutea.

Long acting biologically active luteinizing hormone (LH) compound

Gla domain variants of human Factor VII or human Factor VIIa, comprising 1-15 amino acid modifications relative to the human Factor VII or human Factor VIIa sequence shown in SEQ ID NO:1, wherein a hydrophobic amino acid residue has been introduced by substitution in position 34; or having an amino acid substitution in position 36; and use of the variants for the treatment of intracerebral haemorrhage (ICH) or trauma.

Factor VII or Factor VIIa Gla domain variants

Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.

Factor VII or VIIA-like molecules

The present invention relates to a method for improving the properties of a cellulolytic enzyme by amino acid substitution, deletion or insertion, the method comprising the steps of:

Cellulase variants

Gla domain variants of human Factor VII or human Factor VIIa, comprising 1-15 amino acid modifications relative to human Factor VII or human Factor VIIa, wherein a hydrophobic amino acid residue has been introduced by substitution in position 34 or having an amino acid substitution in position 36 of the amino acid sequence shown in SEQ ID NO:1; and use of the variants for the treatment of intracerebral haemorrhage (ICH) or trauma.

Factor V11 or factor V11A GLA domain variants

Variants of FVII or FVIIa comprising at least one amino acid modification in position 196, 237 or 341 relative to hFVII or hFVIIa. The variants exhibit an increased clotting activity, i.e. reduced clotting time, compared to rhFVIIa.

FVII or FVIIa variants

Factor VII or VIIa&#x2014;like molecules

The present invention relates to novel polypeptide variants of factor VII (FVII) or factor VIIa (FVIIa) polypeptides, where said variants comprise an amino acid substitution in position 10 and 32 and where said variants further comprise a sugar moiety covalently attached to an introduced in vivo N-glycosylation site located outside the Gla domain. Such polypeptide variants are useful in therapy, in particular for the treatment of a variety of coagulation-related disorders, such as trauma.

Polypeptide conjugates with G-CSF activity comprising a polypeptide having at least one introduced lysine residue and at least one removed lysine residue compared to the sequence of human G-CSF, and which are conjugated to 2-6 polyethylene glycol moieties. The conjugates have a low in vitro bioactivity, a long in vivo half-life, a reduced receptor-mediated clearance, and provide a more rapid stimulation of production of white blood cells and neutrophils than non-conjugated recombinant human G-CSF.

G-CSF conjugates

Growing community of inventors

Broenshoej, Denmark

Kim Vilbour Andersen